This article is more than 5 years old. Information may no longer be current.
VIDEO: Treatment of patients with cancer-associated thrombosis an ‘evolving paradigm’
CHICAGO — Alok A. Khorana, MD, professor of medicine at Cleveland Clinic Lerner College of Medicine, vice chair for clinical services of Taussig Cancer Institute and director of the gastrointestinal malignancies program at Cleveland Clinic, discusses studies that evaluate the treatment and prevention of cancer-associated thrombosis presented at the ASCO Annual Meeting.
“Patients with cancer are very likely to get blood clots, about one in five cancer patients will get a blood clot at some point during the course of their treatments,” he said. “How to treat these patients is an evolving paradigm.”
Khorana and colleagues evaluated the association between the duration of anticoagulation and venous thromboembolism recurrence, in which the extension of anticoagulation beyond 3 months reduced risk for recurrent clots in patients with cancer.
In addition, Khorana discusses which therapeutic agents are associated with the best outcomes, and which novel oral agents have been well tolerated.